Ibaraki, Japan

Yoshihiko Uesaka


 

Average Co-Inventor Count = 4.5

ph-index = 2

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 2005-2021

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Yoshihiko Uesaka

Introduction

Yoshihiko Uesaka is a notable inventor based in Ibaraki, Japan. He has made significant contributions to the field of nucleic acid detection and immunochromatography. With a total of 2 patents, his work has advanced the methodologies used in these areas.

Latest Patents

Uesaka's latest patents include a method for nucleic acid detection or quantification using mask oligonucleotides. This innovative approach allows for very simple and highly sensitive detection of target nucleic acids. By hybridizing mask oligonucleotides to specific regions of a nucleic acid, he has developed a technique that stabilizes the single-stranded region while allowing for effective probe hybridization. Additionally, he has patented a housing for an immunochromatography apparatus. This housing is designed to detect low concentrations of analytes in samples, featuring an observation window made of colored transparent plastic that enhances visibility of detection lines.

Career Highlights

Throughout his career, Uesaka has worked with prominent companies such as Nissui Pharmaceutical Co., Ltd. and Fuso Pharmaceutical Industries, Ltd. His experience in these organizations has contributed to his expertise in the field of pharmaceuticals and diagnostics.

Collaborations

Uesaka has collaborated with notable colleagues, including Yuichi Oku and Kumiko Shinohara. These partnerships have likely enriched his research and development efforts.

Conclusion

Yoshihiko Uesaka's contributions to nucleic acid detection and immunochromatography demonstrate his innovative spirit and commitment to advancing scientific knowledge. His patents reflect a deep understanding of the complexities involved in these fields, making him a significant figure in modern invention.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…